Kornimate/medical-research-clean huggingface dataset:
effect of aging and aerobic fitness level on heat dissipation

Conditions: Risk of Heat Stress

Summary: in the context of global aging, the health risk factors associated with exercising or working in the heat for aging population are exacerbated by the rising in global surface temperatures. the purpose of this investigation is to determine at what age the heat loss decrements occur and to examine if aerobic fitness level can affect the heat loss capacity in neutral environmental conditions.

all trials were conducted to indoor gyms with the same environmental temperature and relative humidity, 26 - 30oc and 40-50% respectively, to ensure no difference in body temperature were due to the external thermal stress. the participants were instructed to refrain from intense exercise as well as alcohol and caffeine consumption for 24 hours prior to experimental trial and to had a light meal 2h before their arrival. upon arrival, participants would have to wear running shoes, light and short running shorts and light cotton socks. participants received comprehensive instructions about the shuttle run test and the whole process of measurements. firstly participants answered the international physical activity questionnaire (ipaq). thereafter, anthropometrics data (weight and height) were evaluated as well as the body temperature in external ear canal and axillary. all participants followed five minutes warming up and then performed to 20 m shuttle run test until their volitional limit. once the participants could no longer run, the test was over and the number of laps was recorded. after the end of the shuttle run, were evaluated the body temperature and the weight of each participants. no fluids consumptions were permitted until the second weighing. they were weighed twice, at baseline and at the end of the running test with a precision weight scale (kern de 150k2d, kern \& sohn gmbh, balingen, germany). environmental data including air temperature and relative humidity were measured continuously using a portable weather station (lcd digital temperature \& humidity meter htc-1). the weather station was placed 1 meter above the ground according to the manufacturer's guidelines.

Eligibility criteria:
inclusion criteria: * healthy children and adults exclusion criteria: * diagnosed chronic medical condition; * symptoms of acute illness; * recent (past 4 weeks) usage of medications known to affect the circulatory system, the thyroid, the pituitary function, or the metabolic status

Keywords: heat loss aging aerobic fitness level heat stress
validation of pediatric sleep questionnaire on a swedish cohort

Conditions: Obstructive Sleep Apnea; Sleep Disorder; Sleep Disorders in Children; Obstructive Sleep Apnea of Child

Summary: this study is aimed to validate the questionnaire called pediatric sleep questionnaire on a swedish cohort of children from 18 months to 15 years old with obstructive sleep disordered breathing.


Eligibility criteria:
inclusion criteria: * children with osdb-symptoms referred to ent-clinics * age between 18 months and 15 years old. * good knowledge of the swedish language exclusion criteria: * craniofacial abnormalities * mb down * neuromuscular disorders * do not understand swedish

Keywords: osdb psq pediatrics
omega-3 fatty acids in sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to determine the safety of a new formulation of the omega-3 fatty acids docosahexaenoic acid (dha) and eicosapentaenoic acid (epa) and to assess whether it decreases inflammation and inflammatory pain in children and young adults with sickle cell disease.


Eligibility criteria:
inclusion criteria: subjects who meet all of the following criteria are eligible for enrollment into the study: * participant has signed the informed consent/assent with parent signing informed consent as age appropriate. * established diagnosis of hbss, hbsc or hbsβo thalassemia * history of ≥1 vasoocclusive events (managed at home and/or in hospital) in preceding 12 months. * regular compliance with comprehensive care. * aged 8 years or greater and less than 26 years. * at enrollment, subject should be in his/her baseline steady state and not in the midst of any acute complication due to scd. must be at least 2 weeks from infection or vasoocclusive crisis at time of screening labs exclusion criteria: * baseline hemoglobin levels \<5.5 gm/dl. * inability to swallow capsules * poor compliance with previous treatment regimens. * hepatic dysfunction * renal dysfunction * pt and/or ptt ≥ 20% outside of normal * allergy to fish, shell fish or soy * triglyceride levels \<80mg/dl. * pregnancy. * chronic transfusion therapy. * transfusion within the last 30 days. * treatment with any investigational drug or regular fish oil supplementations in last 60 days. * currently receiving another investigational agent, or on such an agent with the last 60 days. * dosage changes in preceding 3 months if on hydroxyurea * diagnosed bleeding disorder or patient on concomitant anti-coagulation. * conditional or abnormal result on most recent transcranial doppler or history of stroke. * other active chronic illness that could adversely affect subjects performance * children in care * platelet count less than 100,000

Keywords: sickle cell disease omega-3 fatty acids docosahexaenoic acid (dha) eicosapentaenoic acid (epa)
goal-directed resuscitative interventions during pediatric inter-facility transport (the gripit trial)

Conditions: SIRS (Systemic Inflammatory Response Syndrome(

Summary: recent advances in critical care medicine have dramatically improved morbidity and mortality of critical illness. goal-directed therapy protocols have been instrumental in this change. goal-directed therapy standardizes the rapid delivery of definitive care in illnesses such as sirs (systemic inflammatory response syndrome) and head trauma. although this treatment approach has been shown to improve clinical outcomes, it has not been widely adopted outside academic medical centers. further improvement in outcomes of critical illness is likely if goal-directed therapy is utilized early in the course of care. to facilitate this early adoption, goal-directed therapeutic protocols should be developed and implemented by specialized pediatric transport teams. the investigators hypothesize that the institution of goal-directed therapy during pediatric interfacility transport will improve the outcomes of critically ill children. the gripit trial (goal-directed resuscitative interventions during pediatric inter-facility transport) will compare outcomes of pediatric sirs patients before and after the implementation of a goal-directed therapeutic protocol during transport. this will be the first test of goal-directed therapy in the transport environment. data will be collected on pediatric sirs patients transported by the angel one transport team at arkansas children's hospital before and after protocol implementation. outcome measures will include length of hospital stay, length of intensive care unit (icu) stay, incidence of multiple organ dysfunction syndrome (mods), and required therapeutic interventions during icu stay (tiss-28 scores). in addition, nirs (near-infrared spectroscopy) monitoring will be used as a cerebral and somatic oxygenation trend monitor, to determine its effectiveness as a resuscitation guide for pediatric sirs during transport. nirs trends are useful as a surrogate marker for systemic venous saturations, known to decrease with severe sirs.


Eligibility criteria:
inclusion criteria: * pediatric patients transported to arkansas children's hospital by the angel one transport team * age group: 1 month - 17 years * systemic inflammatory response syndrome (age-specific sirs criteria) exclusion criteria: * known or suspected congenital heart disease * known or suspected cardiomyopathy or myocarditis * diabetic ketoacidosis (dka) as sirs-inducing illness * traumatic brain injury (tbi) as sirs-inducing illness * burn injury as sirs-inducing illness * patients with known or suspected active hemorrhage

Keywords: sirs shock sepsis pediatric inter-facility transport specialized transport nirs monitoring
a study of tq05105 tablets in subjects with myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasms

Summary: tq05105 is a jak2 inhibitors and can be used to treat jak2 target-related diseases. the activation of the jak/stat pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.


Eligibility criteria:
inclusion criteria: * 1.18 years and older; eastern cooperative oncology group (ecog) performance status of 0 to 3; life expectancy ≥ 3 months. 2. diagnosed as primary myelofibrosis(pmf), polycythemia vera(pv), essential thrombocythemia(et), post-polycythemia vera myelofibrosis (ppv-mf) or post- essential thrombocythemia myelofibrosis (pet-mf). 3. myelofibrosis at intermediate risk -1 and above according to dynamic international prognostic scoring system(dipss); pv or et were resistant or intolerant to hydroxyurea and/or interferon therapy. 4. adequate hematology laboratory index. 5.the most prominent part of the spleen ≥ 5cm to the lower edge of the ribs. 6.bone marrow blasts and peripheral blood blasts \<20%. 7. appropriate liver and kidney functions. 8.the main blood coagulation function is appropriate. 9. those who have used other mpn treatment drugs before first dose need to stop exceed 2 weeks. those who have received major surgery before first dose need to exceed 4 weeks. 10.no pregnant or breastfeeding women, and a negative pregnancy test. 11.understood and signed an informed consent form. exclusion criteria: * 1. has diagnosed and/or treated additional malignancy within 5 years prior to randomization. with exception of non-melanoma, skin cancer, and carcinoma in situ. 2. has participated in other anticancer drug clinical trials within 4 weeks. 3. has multiple factors affecting oral medication. 4. has drug abuse history that unable to abstain from or mental disorders. 5. has active hepatitis b or c, or immunodeficiency. 6. has immunodeficiency. 7. has arteriovenous thrombosis events within 4 weeks. 8. has received long-term and large-dose glucocorticoids or other immunosuppressive drugs within 28 days before signed the informed consent form. 9. has serious systemic infections. 10. has uncontrolled cardiovascular disease. 11. has uncontrolled hypertension. 12. has serious systemic infections. 13. according to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
the role of secretin on the energy homeostasis

Conditions: Obesity; Metabolic Disease; Diabetes; Adiposity

Summary: as of last year, new insight into the function of secretin was brought about as rodent studies showed secretin to possess potential body weight-regulating effects. in these studies, secretin was shown to increase non-shivering thermogenesis in brown adipose tissue (bat), decrease meal size and promote meal discontinuation. the mechanisms behind these regulatory effect of secretin on energy homeostasis are unclear,

secretin was - as the first hormone - identified in 19021, but was not isolated until the 1960s. secretin is produced in and secreted form small intestinal s cells. in the 1970s, the primary endocrine effects of secretin were unequivocally confirmed, namely potentiation of bicarbonate and pepsin secretion from the pancreas as well as stimulation of bile production in the liver. in the 1990s, the biosynthesis of secretin was delineated and its receptor was discovered. in the 2000s the pancreatic regulation of intestinal ph was shown to be secretin-mediated. as of last year, new insight into the function of secretin was brought about as rodent studies showed secretin to possess potential body weight-regulating effects. in these studies, secretin was shown to increase non-shivering thermogenesis in brown adipose tissue (bat), decrease meal size and promote meal discontinuation. the primary aim of this study is to evaluate the effect of a 5-hour intravenous infusion with the naturally occurring hormone secretin on ad libitum food intake (primary endpoint) compared to a double-blinded placebo (isotonic saline) infusion in 25 healthy young males.

Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * body mass index between 18.5 and 27.5 kg/m2 * informed consent * body weight above 50 kg exclusion criteria: * anaemia (blood haemoglobin below normal range) * known liver disease and/or alanine aminotransferase and/or aspartate transaminase \> 2 times upper normal values * nephropathy (serum creatinine above normal range and/or albuminuria) * clinically significant kidney function impairment or other laboratory findings leading to the diagnosis of clinically relevant disorders (thyroid dysfunction, anaemia etc) * any physical or psychological condition that the investigators feel would interfere with trial participation
prevalence and significance of mutations in genes encoding napi-co-transporters in the development of cavd

Conditions: Aortic Valve Calcification; Aortic Stenosis

Summary: mutations in the slc34a2 gene, that encodes the sodium phosphate co-transporter (napi-iib), cause defect cell-uptake of phosphate, which leads to formation of calcium-phosphate concretions in the lungs as seen in pulmonary alveolar microlithiasis (pam). extra pulmonary calcifications, including heart valve calcification, have previously been reported in patients with pam. calcific aortic valve disease (cavd) is a common disease in the elderly and is characterised by thickening and calcification of the aortic valve leaflets in the absence of rheumatic heart disease. cavd is present in more than 25% of patients older than age 65 years and is associated with an increased risk of cardiovascular events. currently, there is no effective therapy for the disease other than surgical aortic valve replacement. both calcium and phosphate are the major components of calcific deposits in pam and cavd. based on these preliminary findings, the investigators hypothesize that mutations in sodium phosphate co-transporters may play a role in both pulmonary and extra pulmonary calcifications. two studies will be performed: 1. a retrospective cross-sectional study including patients with an age ≤ 65 years with cavd from denmark and örebro, will be carried out. genetic association analysis will be performed to investigate the incidence of common variants in five genes representing sodium phosphate co-transporters (slc34a1, slc34a2, slc34a3, slc20a1, slc20a2) compared to healthy controls. associated genes will subsequently be sequenced to identify possible causal mutations. 2. in a prospective study, aortic valve tissue will be collected from patients with as undergoing surgical valve replacement. molecular characterisation of the transporters will be conducted by determining the level of specific mrna and protein by rt-pcr/qpcr, and western blotting, respectively. the localisation and visualisation will be investigated by immunostaining and confocal laser microscopy. fibroblasts and endothelial cells will be isolated and grown in cultures with subsequent functional studies of the phosphate uptake.


Eligibility criteria:
inclusion criteria: * aortic valve calcification * informed consent before study participation * age: ≥ 18 years ≤ 65 years exclusion criteria: * lacking ability to give informed consent * radiotherapy towards the thorax * severe kidney disease (in dialysis)
potential effects of intermittent fasting to metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the survey is designed to investigate whether 8 weeks of discrete two-day intermittent fasting per week will impact gut microbiota and cardiovascular risks of metabolic syndrome subjects.

intermittent fasting was demonstrated to optimize energy metabolism and promote health. however, the benefits of intermittent fasting to gut microbiota are remain unclear. further evidence is needed in understanding the effects of intermittent fasting to gut microbiota and cardiovascular risks in subjects with metabolic syndrome

Eligibility criteria:
inclusion criteria: * local residents aged between 30 to 50 years old * stable body weight (change \<±10% of body weight) for 3 months before the study * central obesity: waist circumference ≥90 cm in males or ≥80 cm in females; plus any two of the following four conditions: 1. elevated triglycerides: serum triglycerides ≥150 mg/dl (1.7 mmol/l) 2. reduced hdl cholesterol: serum hdl-c \<40 mg/dl (1.03 mmol/l) in males or \<50 mg/dl (1.29 mmol/l) in females 3. elevated blood pressure: systolic blood pressure ≥130 mmhg or diastolic blood pressure ≥85 mmhg or receiving medication of hypertension 4. elevated fasting plasma glucose: fasting plasma glucose ≥100 mg/dl (5.6 mmol/l) exclusion criteria: * history of cardiovascular and cerebrovascular diseases * acute or chronic infectious diseases within 4 weeks * known malignant tumor * alcohol abuse (weekly consumption of alcohol is more than 70 g in females or 140 g in males) * regular therapy with antihypertensive drug, hypolipidemic agents, hypoglycemic agents, hormonal agents and antidepressants within 6 months * use of probiotics, prebiotics or antibiotics within 3 months and in progress of study * use of antiinflammatory drug in progress of study * following a vegetarian diet or veganism * women who are pregnant or intend to be pregnant during the research
emergency medical services (ems) telehealth to speed stemi reperfusion

Conditions: STEMI - ST Elevation Myocardial Infarction

Summary: the aim of this study is to evaluate the impact of a telehealth program on the time from first medical contact (fmc) to reperfusion in stemi (st-elevation myocardial infarction) patients, by supporting local paramedics in their care delivery.

stemi (st-elevation myocardial infarction) is the most severe type of heart attack and carries a 30-day mortality of nearly 8%. reperfusion therapy is the mainstay of treatment for stemi, either by percutaneous coronary intervention (pci) or fibrinolytics. delays in reperfusion are associated with negative health outcomes. specifically, each 30-minute delay in reperfusion corresponds to a 7.5% decrease in 1-year survival. the current body of literature clearly shows that rural ems agencies often have longer transport times, which makes the 90-minute first medical contact (fmc) to pci time goal difficult to achieve. approximately 16% of americans live more than an hour from a pci-capable facility, reinforcing the need for timely therapies in rural prehospital settings to decrease heart muscle damage (disability) and mortality. an analysis of a large national ems database, which showed that fmc to pci times were longer for patients treated by rural ems agencies even after these times were adjusted for distance to destination hospital.8in addition, preliminary data for cherokee tribal ems, serving the eastern band of cherokee indians on the qualla boundary and its surrounding communities, show that none of their patients who called 9-1-1 for a stemi received reperfusion within the aha time goal. the american college of cardiology and aha support prehospital fibrinolytics when timely pci cannot be performed. stemi telehealth programs have yet to be implemented and tested in the united states.

Eligibility criteria:
inclusion criteria: * all patients calling 9-1-1 in wilkes county with possible stemi as determined by the on scene paramedics will be included in the data. exclusion criteria: * as this is a quality surveillance study, subjects will not be excluded.

Keywords: heart attack reperfusion therapy percutaneous coronary intervention
measuring and evaluating the changes in anxiety levels of children with repetitive sessions of dental treatments

Conditions: Dental Anxiety

Summary: dental anxiety is defined as the fear of terrible events during dental treatment and the loss of control.anxiety may be related to adaptation of the patient to external factors in environment, so the adaptation of the pediatric patient to the stimuli in the dental environment may affect the level of anxiety.the aim of the this study was to evaluate the relationship between sequential visits in dental treatments and dental anxiety levels of pediatric patients with anxiety scales and physiological measurements.

a total of 224 children aged 5-8 years who needed at least two restorative dental treatment of the mandibular first primary molar were included in the study. in each sessions the wong-baker faces pain rating scale (w-bfrs) was used to evaluate the dental anxiety before and after the treatment. the modified corah's dental anxiety scale (mdas) was used as a dental anxiety measurement method. a portable finger pulse oximeter (nellcor™ pmn10, medtronic corp. mn, usa) was used to measure the heart rate. data were statistically analyzed with the help of the statistical package for social sciences statistical software (spss 18.0), considering a 5% significance level. nonparametric tests were used. normality assumption was evaluated with the kolmogorov smirnov test. the association between two groups was analyzed by wilcoxon signed rank test.

Eligibility criteria:
inclusion criteria: * children aged 5-8 years * children who need at least two restorative dental treatments of the mandibular first primary molar exclusion criteria: * chronic systemic illnesses * dental experience * mental disorders * invasive medical treatments * hospitalization * oral health problems with a painful history
mechanistic study of subclinical hypothyroidism in the elderly

Conditions: Subclinical Hypothyroidism

Summary: subclinical hypothyroidism, defined as an elevated tsh in the setting of normal thyroid hormone levels, is a common diagnosis in the elderly. the purpose of this study is to examine the hypothalamic-pituitary-thyroid axis in men and women aged 70 years and older with persistent subclinical hypothyroidism. to evaluate the mechanism behind this condition, participants will undergo thyrotropin releasing hormone stimulation testing at 3 visits: baseline and while taking two different thyroid hormone preparations, levothyroxine and liothyronine. the investigators will also assess physiologic responses to these two different thyroid hormone medications to help us understand how the thyroid works in advanced age.


Eligibility criteria:
inclusion criteria: 1. men and women aged 70 and older 2. tsh between 4.5 and 19.9 mu/l as an outpatient 3. ability to provide informed consent exclusion criteria: laboratory tests: 1. tsh \ 20 mu/l on repeat testing at least four weeks later or free t4 level outside the reference range 2. thyroid peroxidase (tpo) antibody positive 3. abnormal liver function tests (lfts \>3 x upper limit of normal) 4. hemoglobin \<11 g/dl surgeries or procedures: 1. thyroid surgery 2. pituitary surgery 3. bariatric surgery 4. bowel resection involving the jejunum and upper ileum 5. radioactive iodine therapy 6. radiation treatments to head or neck medical conditions: 1. diagnosis of pituitary disease 2. diagnosis of amyloidosis, sarcoidosis, hemochromatosis 3. diagnosis of adrenal insufficiency 4. obesity with bmi \> 35 mg/kg2 5. history of stroke 6. chronic or ongoing angina, class ii or higher congestive heart failure, or uncontrolled hypertension with current blood pressure greater than 160/100 7. diabetes mellitus with hemoglobin a1c level greater than 8.0% in the past six months 8. celiac sprue, crohn's disease, ulcerative colitis, zollinger-ellison syndrome 9. renal insufficiency with calculated glomerular filtration rate \<45 cc/min 10. cognitive impairment with mini mental state exam\[30\] \<24/30 11. history of any seizures 12. unstable medical or psychological condition in the judgment of the principal investigator medications: 1. thyroid hormone preparations 2. antithyroid drugs 3. medications that interfere with the absorption or metabolism of thyroid hormone 4. medications that interfere with the trh stimulation test 5. proton pump inhibitors

Keywords: levothyroxine liothyronine thyrotropin releasing hormone aging hypothyroidism thyroid diseases